Half of renally-cleared rivaroxaban is cleared as unchanged drug and half as inactive metabolites. ‡Potent inhibitors of both CYP3A4 and P-gp include azole antifungals (e.g., ketoconazole ...

rivaroxaban, 0.38 [95% confidence interval {CI}, 0.24 to 0.60]; hazard ratio for 90-mg abelacimab vs. rivaroxaban, 0.31 [95% CI, 0.19 to 0.51]; P<0.001 for both comparisons). The incidence and ...

Four years ago, protein drug developer Zymogenetics in Seattle began developing a recombinant version of the blood-clotting protein thrombin. On 17 January, it received US marketing approval for ...

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...

dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors), before, during and after dental treatment in light of the more recent knowledges. Discussion ...

Find our full coverage below. PHILADELPHIA, PA—The novel factor XI inhibitor abelacimab, given subcutaneously once a month, is far less likely to lead to major and nonmajor clinically relevant ...